Neiyanggong reduces cancer-related fatigue and improves sleep quality in breast cancer patients undergoing chemotherapy.
A randomized controlled trial of 72 breast cancer patients undergoing chemotherapy found that a staged progressive dynamic-static Neiyanggong intervention significantly reduced cancer-related fatigue (PFS-R total score interaction effect F=94.810, P<0.001, η²=0.807) and improved sleep quality (PSQI total score interaction effect Wald χ²=292.975, P<0.001) compared to routine care. After three chemotherapy cycles, fatigue scores were significantly lower in the Neiyanggong group (P<0.05), and notable improvements were seen in sleep latency, sleep efficiency, and daytime dysfunction (P<0.001).
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Neiyanggong reduces cancer-related fatigue and improves sleep quality in breast cancer patients undergoing chemotherapy. The current body of evidence comprises 1 study, including 1 randomized controlled trial. EvidenceHub rates the overall confidence at 44/100 (low).
The Claim
Neiyanggong reduces cancer-related fatigue and improves sleep quality in breast cancer patients undergoing chemotherapy.
This conclusion is most relevant to: Breast cancer patients undergoing chemotherapy (n=72, 36 per group)..
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Effects of Neiyanggong on cancer-related fatigue in breast cancer patients undergoing chemotherapy: a randomized controlled trial. (Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026) — A randomized controlled trial of 72 breast cancer patients undergoing chemotherapy found that a staged progressive dynamic-static Neiyanggong intervention significantly reduced cancer-related fatigue (PFS-R total score interaction effect F=94.810, P<0.001, η²=0.807) and improved sleep quality (PSQI total score interaction effect Wald χ²=292.975, P<0.001) compared to routine care. After three chemotherapy cycles, fatigue scores were significantly lower in the Neiyanggong group (P<0.05), and notable improvements were seen in sleep latency, sleep efficiency, and daytime dysfunction (P<0.001).
How It Works
The proposed biological pathway:
- ▸Neiyanggong combines dynamic and static exercises tailored to disease characteristics
- ▸Practiced progressively over three chemotherapy cycles
- ▸May reduce fatigue and improve sleep through mind-body regulation and physical activity
- ▸Result: Significant reduction in fatigue and improvement in sleep quality
Who Might Benefit
Evidence fit by population:
- ▸Breast cancer patients undergoing chemotherapy (n=72, 36 per group).
Recommended Dose
N/A
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Single-center study with relatively small sample size (n=72)
- ▸No blinding of participants or practitioners due to the nature of the intervention
Frequently Asked Questions
What is Neiyanggong?▼
Neiyanggong is a mind-body exercise combining dynamic and static movements, adapted here as a staged progressive intervention for breast cancer patients.
How was sleep quality measured in this study?▼
Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI), which evaluates components like sleep latency, sleep efficiency, and daytime dysfunction.
Did the Neiyanggong group experience any side effects?▼
No adverse events occurred in the Neiyanggong group, and adherence to the intervention was high.
Is this intervention suitable for all breast cancer patients?▼
The study focused on patients undergoing chemotherapy, and the intervention was tailored to disease-specific characteristics. Generalizability may be limited by the single-center design and small sample size.
References
- 1.Du Y, Wang J, Zhang C, Guo Q, Hao X, Zhang W, Jiao G. “Effects of Neiyanggong on cancer-related fatigue in breast cancer patients undergoing chemotherapy: a randomized controlled trial..” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. PMID: 42498825 DOI: 10.1007/s00520-026-11029-7